KLOW = KPV + the GLOW three
Taking a proactive approach will empower you to make informed choices, allowing for a harmonious balance between your health and prescribed treatments
However, it is also a dual-action drug and includes a GIP activator element
For patients using GLP-1 medications for type 2 diabetes, hemoglobin A1c may increase after discontinuation if no alternative therapy is initiated, with the magnitude varying based on individual factors and baseline therapy
To understand Key Opinion Leaders perspectives around the accessibility and acceptability of emerging treatment options along with GLP-1 agonists unmet need of current therapies Details on report methodology, top indications covered, market assumptions, patient journey and KOLs to strengthen the pharmaceutical companies development and launch strategy.
Look for ongoing lifestyle support